NCT04459572View on ClinicalTrials.gov

As an Early Indicator Biomarker of Prognosis and Mortality in Children With Sepsis and Septic Shock: suPAR

NACompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

March 27, 2019

Primary Completion Date

September 27, 2019

Study Completion Date

June 25, 2020

Conditions
Septic ShockSepsis, Severe
Interventions
DIAGNOSTIC_TEST

suPAR

Soluble Urokinase Plasminogen Activator Receptor (suPAR)

Trial Locations (1)

35100

Ege University School of Medicine, Izmir

All Listed Sponsors
lead

Ege University

OTHER

NCT04459572 - As an Early Indicator Biomarker of Prognosis and Mortality in Children With Sepsis and Septic Shock: suPAR | Biotech Hunter | Biotech Hunter